Novavax (NasdaqGS:NVAX) recently announced its earnings for Q4 2024, showing a significant improvement in net loss and loss per share, which may have positively influenced its stock price movement.

Novavax (NVAX) has recently seen a decrease in stock value, dropping after announcing Q4 results that missed revenue expectations. The company ...

Novavax Inc (NVAX) outlines its strategic focus on partnerships and pipeline expansion while navigating revenue fluctuations ...

Shares of Novavax Inc. NVAX advanced 5.97% to $8.34 Friday, on what proved to be an all-around positive trading session for ...

B. Riley cut their Q1 2025 earnings per share estimates for Novavax in a report issued on Monday, March 3rd. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will post ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Novavax (NVAX) stock jumped today following the release of the vaccine maker’s Q4 2024 earnings report. That follows its diluted earnings per ...

NVAX reports encouraging fourth-quarter results. It completes the sale of its Czech Republic manufacturing unit to Novo ...

Novavax (NVAX) stock in focus as company beats Q4 revenue forecasts despite an 80% drop in product sales. Read more here.